From Demyelination to Intervention: Natural Compounds as Emerging Therapeutic Targets in Multiple Sclerosis Neuroinflammation - PubMed
5 hours ago
- #natural compounds
- #neuroinflammation
- #multiple sclerosis
- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system causing demyelination and neurological dysfunction.
- B lymphocytes and dysregulated cytokine networks (e.g., Th17/IL-17, NF-κB) are key drivers of MS pathogenesis.
- Current disease-modifying therapies (DMTs) have limitations due to side effects, dependency, and inadequate long-term efficacy.
- Natural compounds (alkaloids, flavonoids, terpenoids, polyphenols) show promise for MS treatment due to biocompatibility, safety, and multi-target effects.
- This review evaluates natural compounds in MS, focusing on common pathways like NF-κB inhibition and Th17/Treg balance modulation.
- Experimental autoimmune encephalomyelitis (EAE) models have limitations in replicating human MS pathophysiology.
- Future perspectives include combining natural products with existing DMTs, addressing clinical trial challenges, and exploring combination therapies.